RESULTS OF ADJUVANT PACLITAXEL AND CARBOPLATIN AFTER CONCURRENT CHEMO RADIATION (CCRT) IN LOCALLY ADVANCED CERVICAL CANCER (LACC)

  • Professor & Head, Department of Radiotherapy and Oncology, Department of P.S.M, Government Medical College and Cancer Hospital Aurangabad, Maharashtra.
  • Associate Professor, Department of Radiotherapy and Oncology, Department of P.S.M, Government Medical College and Cancer Hospital Aurangabad, Maharashtra.
  • Resident, Department of Radiotherapy and Oncology, Department of P.S.M, Government Medical College and Cancer Hospital Aurangabad, Maharashtra.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Concurrent chemo radiation (CCRT) is the standard treatment for locally advanced cervical cancer (LACC) FIGO stage IIB-IVA.However, failure rate after treatment is still as high as 30% to 40% of which local and distant failures are 17% and 18% respectively and the 5-year survival is still poor.Aim of incorporating adjuvant chemotherapy (ACT) is to target the residual disease in the pelvis and to treat occult disease outside the pelvis. Objective: This study aims to evaluate the feasibility and benefit of adjuvant chemotherapy (ACT) after CCRT in such patients to the improve treatment outcome. Material and Methods: From July 2017-June 2018, eighty patients of LACC were prospectively evaluated. All patients received radiation upto 50Gy with Cisplatin 40 mg/ m2 followed by intra-cavitary radiotherapy- 3fractions of 7 Gy each (28 Gy equivalent). Adjuvant chemotherapy with Paclitaxel (175 mg/m2) +Carboplatin (AUC 5) was planned for all patients to a median of four cycles (range 3?6 cycles). Results: Eighty evaluable patients were enrolled for adjuvant chemotherapy. Disease-free survival after a median follow-up of 14 months (range 8-20) was 83.75% showing a significantly long term tumor control. The adjuvant chemotherapy was well tolerated. Hematologic and neurologic toxicities were most common side effects in our study however, they were manageable. Conclusion: Incorporating adjuvant chemotherapy with Paclitaxel and Carboplatin after concomitant chemoradiation is effective, safe and may be a very promising treatment protocol for advanced cervical cancer.

  1. Ferlay J, Soerjomataram I, Ervik M, et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11.Lyon, France: http://globocan.iarc.fr. Accessed on 04 Sep 2014
  2. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration.Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.JClinOncol2008?26:?5802?5812
  3. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends.?Cancer Epidemiol Biomarkers Prev.?201019:1893?907.?[PubMed]
  4. Rose PG, Bundy BN, Watkins EB, Thigpen JT, DeppeG,Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340: 1144-1153, 1999. deVoset al: Radio-chemotherapy for Primary Cervical Cancer.
  5. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic andpara-aortic radiation for high-risk cervical cancer. N Engl J
  6. Keys HM, Bundy BN, Stehman FB, Muderspach LI, ChafeWE, Suggs CL III, Walker JL and Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340: 1154-1161, 1999.
  7. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. 2000 18:1606?1613.
  8. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynaecologic Oncology Group 240) Tewari K S et al.?2017 Oct 7390(10103):1654-1663.
  9. Vrdoljak E, Omrcen T, Novaković ZS, Jelavić TB, Prskalo T, Hrepić D, et al. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix--final results of a prospective phase II-study. GynecolOncol 2006103:494-9.
  10. Due?as-Gonz?lez A,Zarb?JJ,?Patel F?et al.??Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.?J ClinOncol2011?29:?1678?1685.
  11. Choi CH, Lee YY, Kim MK, Kim TJ, Lee JW, Nam HR, et al. A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer.Int J RadiatOncolBiolPhys 201181:1252-7.
  12. SZhang MQ, Liu SP, Wang XE. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study. Int J RadiatOncolBiolPhys 201078:821-7.
  13. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R and Kavanagh JJ: An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 8: 657-661, 1997.
  14. McGuire WP, Blessing JA, Moore D, Lentz SS and Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer.A Gynaecologic Oncology Group study. J ClinOncol14: 792-795, 1996.
  15. Chen MD, Paley PJ, Potish RA and Twiggs LB: Phase I trial of taxol as a radiation sensitiser with cisplatin in advanced cervical cancer. GynecolOncol67: 131-136, 1997.
  16. Piver MS, Ghamande SA, Eltabbakh GH and O'Neill-Coppola C: First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - a phase II study. GynecolOncol75: 334-337, 1999.
  17. Chougule PB, Akhtar MS, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness J, Radie-Keane K and Wanebo H: Chemoradiotherapy for advanced inoperable head and neck cancer: a phase II study. SeminRadiatOncol9: 58-63, 1999.
  18. Greco FA, Burris HA, III, Gray JR, Raefsky EL, Dobbs C, Smith S, Rinaldi D, Morrissey LH, Erland JB, Litchy S and Hainsworth JD: Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected non-small cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network. Cancer 92: 2142-2147, 2001.
  19. Socinski MA, Rosenman JG, Schell MJ, Halle J, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W and Detterbeck FC: Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I trial. Cancer 89: 534-542, 2000.
  20. Corn BW, Micaily B, Dunton CJ, Heller P, ValicentiRK,Anderson L and Hernandez El: Concomitant irradiation and dose-escalating carboplatin for locally advanced carcinoma of the uterine cervix: an updated report. Am J ClinOncol21: 31-35, 1998.
  21. Muderspach LI, Curtin JP, Roman LD, Gebhardt JA, Klement V, Qian D, Morrow CP, Felix JC, Formenti SC and Muggia FM: Carboplatin as a radiation sensitiser in locally advanced cervical cancer: a pilot study. GynecolOncol65: 336-342, 1997.
  22. Delgado G, Bundy B, Zaino R et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.?GynecolOncol1990 38:352?357.
  23. Zaino RJ, Ward S, Delgado E et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.?Cancer199269:1750?1758.
  24. Burghardt E, Baltzer J, Tulusan AH et al. Results of surgical treatment of 1028 cervical cancers studied with volumetry.?Cancer1992 70:648?655.
  25. Stehman FB, Bundy BN, DiSaia PJ et al. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group.?Cancer199167:2776?2785.
  26. Perez CA, Grigsby PW, and Camel HM et al. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of the uterine cervix: update of a nonrandomized comparison.?Int J RadiatOncolBiolPhys1995 31:703?716.
  27. Fagundes H, Perez CA, Grigsby PW et al. Distant metastases after irradiation alone in carcinoma of the uterine cervix.?Int J RadiatOncolBiol Phys1992 24:197?204.
  28. Pattern of Failure with Locally Advanced Cervical Cancer? A Retrospective Audit and Analysis of Contributory Factors.AnisBandyopadhyay,Asian Pac J Cancer Prev,2017, 19- (1), 73-79
  29. Tangjitgamol S, Tharavichitkul E, Tovanabutra C, Rongsriyam K, Asakij T, Paengchit K, et al. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.?J GynecolOncol.?2019 30:e82.
  30. Available from: https:// clinicaltrials. gov/ ct2/ show/ NCT01566240
  31. Tang J, Tang Y, Yang J, et al. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. GynecolOncol 2012125:297?302.
  32. Cisplatin and radiation therapy with or without carboplatin and paclitaxel in patients with locally advanced cervical cancer. Available from: https:// clinicaltrials. gov/ ct2/ show/ NCT01414608
  33. Jelavić TB, Mi?e BP, Strikic A, et al. Adjuvant chemotherapy in locally advanced cervical cancer after treatment with concomitant chemoradiotherapy--room for Improvement? Anticancer Res 2015 35:4161?5.

[B.K. Shewalkar, Punita Pant, Jitendra Patel, Roopa B. and H. Khadilkar (2020); RESULTS OF ADJUVANT PACLITAXEL AND CARBOPLATIN AFTER CONCURRENT CHEMO RADIATION (CCRT) IN LOCALLY ADVANCED CERVICAL CANCER (LACC) Int. J. of Adv. Res. 8 (Apr). 1086-1093] (ISSN 2320-5407). www.journalijar.com

Dr. Punita Pant
Associate Professor, Department of Radiotherapy and Oncology, Government Medical College and Cancer Hospital Aurangabad, Maharashtra.

DOI:

Article DOI: 10.21474/IJAR01/10880      
DOI URL: https://dx.doi.org/10.21474/IJAR01/10880

Download Full Paper

Download PDF No. of Downloads: 9 | No. of Views: 63